Renal effects of dapagliflozin in patients with type 2 diabetes

Therapeutic Advances in Endocrinology and Metabolism

Volumn 5, Issue 3, 2014, Pages 53-61

  Thomas, Merlin C ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

dapagliflozin; diabetes; diabetic nephropathy; hyperfiltration; SGLT2; SGLT2 inhibition

Indexed keywords

DAPAGLIFLOZIN; EMPAGLIFLOZIN; GLUCOSE; GLUCOSE TRANSPORTER; INSULIN; SODIUM GLUCOSE COTRANSPORTER 1; SODIUM GLUCOSE COTRANSPORTER 2; URIC ACID;

APOPTOSIS; BLOOD PRESSURE; CHRONIC KIDNEY DISEASE; CONTROLLED CLINICAL TRIAL (TOPIC); DIABETIC NEPHROPATHY; FIBROGENESIS; GENE MUTATION; GLOMERULUS FILTRATION RATE; GLUCOSURIA; HUMAN; HYPERGLYCEMIA; INSULIN SENSITIVITY; KIDNEY DISEASE; KIDNEY HYPERTROPHY; KIDNEY PERFUSION; META ANALYSIS (TOPIC); NEPHROLITHIASIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SODIUM ABSORPTION; UPREGULATION; WEIGHT CONTROL;

EID: 84905996272     PISSN: 20420188     EISSN: 20420196     Source Type: Journal    
DOI: 10.1177/2042018814544153     Document Type: Review

References (50)

1. Abdul-Ghani M. Defronzo R. Norton L. (2013) Novel hypothesis to explain why SGLT 2 inhibitors inhibit only 30–50% of filtered glucose load in humans. Diabetes 62: 3324–3328.
2. Afshinnia F. Wilt T. Duval S. Esmaeili A. Ibrahim H. (2010) Weight loss and proteinuria: systematic review of clinical trials and comparative cohorts. Nephrol Dial Transplant 25: 1173–1183.
3. Bailey C. Gross J. Pieters A. Bastien A. List J. (2010) Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 375: 2223–2233.
4. Bello A. de Zeeuw D. El Nahas M. Brantsma A. Bakker S. de Jong P. et al. (2007) Impact of weight change on albuminuria in the general population. Nephrol Dial Transplant 22: 1619–1627.
5. Berry G. Baker L. Kaplan F. Witzleben C. (1995) diabetes-like renal glomerular disease in Fanconi–Bickel syndrome. Pediatr Nephrol 9: 287–291.
6. Boussageon R. Bejan-Angoulvant T. Saadatian-Elahi M. Lafont S. Bergeonneau C. Kassai B. et al. (2011) Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. Br Med J 343: d4169.
7. Cefalu W. (2014) Paradoxical insights into whole body metabolic adaptations following SGLT 2 inhibition. J Clin Invest 124: 485–487.
8. Cheeseman C. (2009) Solute carrier family 2, member 9 and uric acid homeostasis. Curr Opin Nephrol Hypertens 18: 428–432.
9. Chen J. Williams S. Ho S. Loraine H. Hagan D. Whaley J. et al. (2010) Quantitative PCR tissue expression profiling of the human SGLT 2 gene and related family members. Diabetes Ther 1: 57–92.
10. Cherney D. Perkins B. Soleymanlou N. Maione M. Lai V. Lee A. et al. (2014) Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129: 587–597.
11. Coca S. Ismail-Beigi F. Haq N. Krumholz H. Parikh C. (2012) Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in type 2 diabetes. Arch Intern Med 172: 761–769.
12. Defronzo R. Davidson J. Del Prato S. (2012) The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab 14: 5–14.
13. Ehrenkranz J. (2009) Glucose control, the kidney, and potential treatments for diabetes: more to the story. Am J Kidney Dis 54: 583.
14. Ferrannini E. Ramos S. Salsali A. Tang W. List J. (2010) Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 33: 2217–2224.
15. Gerich J. Bastien A. (2011) Development of the sodium-glucose co-transporter 2 inhibitor dapagliflozin for the treatment of patients with type 2 diabetes mellitus. Expert Rev Clin Pharmacol 4: 669–683.
16. Gilbert R. (2013) Sodium-glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering? Kidney Int doi: 10.1038/ki.2013.451.
17. Goicoechea M. de Vinuesa S. Verdalles U. Ruiz-Caro C. Ampuero J. Rincon A. et al. (2010) Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 5: 1388–1393.
18. Groop P. Forsblom C. Thomas M. (2005) Mechanisms of disease: pathway-selective insulin resistance and microvascular complications of diabetes. Nat Clin Pract Endocrinol Metab 1: 100–110.
19. Han S. Susztak K. (2014) The hyperglycemic and hyperinsulinemic combo gives you diabetic kidney disease immediately. Focus on ‘combined acute hyperglycemic and hyperinsulinemic clamp induced profibrotic and proinflammatory responses in the kidney’. Am J Physiol Cell Physiol 306: C198–C199.
20. Holck P. Rasch R. (1993) Structure and segmental localization of glycogen in the diabetic rat kidney. Diabetes 42: 891–900.
21. Hovind P. Rossing P. Johnson R. Parving H. (2011) Serum uric acid as a new player in the development of diabetic nephropathy. J Ren Nutr 21: 124–127.
22. Kambham N. Markowitz G. Valeri A. Lin J. D'Agati V. (2001) Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 59: 1498–1509.
23. Kang D. Nakagawa T. Feng L. Watanabe S. Han L. Mazzali M. et al. (2002) A role for uric acid in the progression of renal disease. J Am Soc Nephrol 13: 2888–2897.
24. Kim Y. Babu A. (2012) Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes. Diabetes Metab Syndr Obes 5: 313–327.
25. Kohan D. Fioretto P. Tang W. List J. (2014) Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 85: 962–971.
26. Kojima N. Williams J. Takahashi T. Miyata N. Roman R.J. (2013) Effects of a new SGLT 2 inhibitor, luseogliflozin, on diabetic nephropathy in T2DN rats. J Pharmacol Exp Ther 345: 464–472.
27. List J. Woo V. Morales E. Tang W. Fiedorek F. (2009) Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 32: 650–657.
28. Malatiali S. Francis I. Barac-Nieto M. (2008) Phlorizin prevents glomerular hyperfiltration but not hypertrophy in diabetic rats. Exp Diabetes Res 2008: 305403.
29. Meinild A. Klaerke D. Loo D. Wright E. Zeuthen T. (1998) The human Na+-glucose cotransporter is a molecular water pump. J Physiol 508: 15–21.
30. Merovci A. Solis-Herrera C. Daniele G. Eldor R. Fiorentino T. Tripathy D. et al. (2014) Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest 124: 2287.
31. Momeni A. Shahidi S. Seirafian S. Taheri S. Kheiri S. (2010) Effect of allopurinol in decreasing proteinuria in type 2 diabetic patients. Iran J Kidney Dis 4: 128–132.
32. Moriya R. Shirakura T. Ito J. Mashiko S. Seo T. (2009) Activation of sodium-glucose cotransporter 1 ameliorates hyperglycemia by mediating incretin secretion in mice. Am J Physiol Endocrinol Metab 297: E1358–E1365.
33. Musso G. Gambino R. Cassader M. Pagano G. (2012) A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med 44: 375–393.
34. Osterby R. Gundersen H. (1975) Glomerular size and structure in diabetes mellitus. I. Early abnormalities. Diabetologia 11: 225–229.
35. Panchapakesan U. Pegg K. Gross S. Komala M. Mudaliar H. Forbes J. et al. (2013) Effects of SGLT 2 inhibition in human kidney proximal tubular cells–renoprotection in diabetic nephropathy? PloS ONE 8: e54442.
36. Patel A., Advance Collaborative Group (2007) Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370: 829–840.
37. Rasch R. Dorup J. (1997) Quantitative morphology of the rat kidney during diabetes mellitus and insulin treatment. Diabetologia 40: 802–809.
38. Rieg T. Masuda T. Gerasimova M. Mayoux E. Platt K. Powell D. et al. (2014) Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT 2 inhibition in euglycemia. Am J Physiol Renal Physiol 306: F188–F193.
39. Riser Taylor S. Harris K. (2013) The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2 diabetes mellitus. Pharmacotherapy 33: 984–999.
40. Scheen A. (2014) Evaluating SGLT 2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations. Expert Opin Drug Metab Toxicol 10: 647–663.
41. Strojek K. Yoon K. Hruba V. Elze M. Langkilde A. Parikh S. (2011) Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab 13: 928–938.
42. Tahrani A. Barnett A. (2012) Dapagliflozin: A sodium glucose cotransporter 2 inhibitor in development for type 2 diabetes. DiabetesTher 1: 1–12.
43. Thomson S. Deng A. Bao D. Satriano J. Blantz R. Vallon V. (2001) Ornithine decarboxylase, kidney size, and the tubular hypothesis of glomerular hyperfiltration in experimental diabetes. J Clin Invest 107: 217–224.
44. Thomson S. Rieg T. Miracle C. Mansoury H. Whaley J. Vallon V. et al. (2012) Acute and chronic effects of SGLT 2 blockade on glomerular and tubular function in the early diabetic rat. Am J Physiol Regul Integr Comp Physiol 302: R75–R83.
45. UK Prospective Diabetes Study Group (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J 317: 703–713.
46. Vallon V. Gerasimova M. Rose M. Masuda T. Satriano J. Mayoux E. et al. (2014) SGLT 2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic akita mice. Am J Physiol Renal Physiol 306: F194–F204.
47. Vallon V. Rose M. Gerasimova M. Satriano J. Platt K. Koepsell H. et al. (2013) Knockout of Na-glucose transporter SGLT 2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus. Am J Physiol Renal Physiol 304: F156–F167.
48. Whaley J. Tirmenstein M. Reilly T. Poucher S.M. Saye J. Parikh S. et al. (2012) Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT 2 inhibition as a new option for treatment of type 2 diabetes mellitus. Diabetes Metab Syndr Obes 5: 135–148.
49. Wilding J. Norwood P. T'Joen C. Bastien A. List J. Fiedorek F. (2009) A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care 32: 1656–1662.
50. Wilding J. Woo V. Pahor A. Sugg J. Langkilde A. Parikh S. (2010) Effect of dapagliflozin, a novel insulin-independent treatment, over 48 weeks in patients with type 2 diabetes poorly controlled with insulin. Diabetologia 53(Suppl.): abstract S348.